149 Bio, LLC is a Miami-based biotechnology company focused on developing integrin activators as innovative therapeutics for kidney diseases. With a mission to address unmet medical needs, their team of experts utilizes a proprietary AI-enabled CellStaple platform to identify novel antibody and small molecule therapeutics.
At the forefront of their pipeline is Ontegimod, a clinical stage, oral, selective, small molecule integrin CD11b agonist designed for the treatment of lupus nephritis. Committed to advancing medical research, 149 Bio offers career opportunities for those looking to contribute to the development of groundbreaking treatments in the field of kidney disease therapeutics.
Generated from the website